Le Lézard
Classified in: Health
Subject: AVO

Congress must act to protect patients' health care access


Statement from Terrence A. Cronin Jr., MD, FAAD, President of the American Academy of Dermatology Association

WASHINGTON, Nov. 2, 2023 /PRNewswire/ -- The Centers for Medicare & Medicaid Services (CMS) finalized cuts to the physician fee schedule for 2024, which will impact the ability of medical practices to cover expenses like equipment, rent, and nursing and office staff salaries. Put plainly, our ability to care for our patients is threatened, putting patients at risk of more hospitalizations for untreated illnesses and chronic conditions. 

As a dermatologist, I see terrible diseases from patients who need immediate attention, otherwise their prognosis can be fatal. If these cuts are allowed to continue, access to their care is threatened.

Medicare finalized a cut of nearly 3.4% in payment for physician services in 2024. For dermatologists, the proposed Medicare cut would affect access to critical skin cancer treatment. Approximately 9,500 people in the United States are diagnosed with this cancer every day.

At the same time, CMS finalized an increase for hospital services of 3.1%.

These cuts to Medicare physician payments, which have occurred over the past 2 years, arise from a complex set of budgetary rules and systemic flaws in the requirements that, unless addressed, will continue to threaten physicians' ability to provide care. These include the budget-neutrality requirement for Medicare mandating that any increase for certain physician services must be balanced by cuts elsewhere.

The 2024 Medicare cuts illustrate physicians' long-time frustration with Medicare. While hospitals and other providers routinely receive inflation-adjusted rates, physicians are facing real payment cuts. The failure of Medicare physician payments to keep up with inflation is the greatest threat to maintaining seniors' access to care.

The AAD calls on Congress to stop these Medicare cuts before more patients will suffer.

About the AAD

Headquartered in Rosemont, Ill., the American Academy of Dermatology, founded in 1938, is the largest, most influential and most representative of all dermatologic associations. With a membership of more than 20,800 physicians worldwide, the AAD is committed to advancing the diagnosis and medical, surgical, and cosmetic treatment of the skin, hair, and nails; advocating high standards in clinical practice, education and research in dermatology; and supporting and enhancing patient care because skin, hair, and nail conditions can have a serious impact on your health and well-being. For more information, contact the AAD at (888) 462-DERM (3376) or aad.org. Follow @AADskin on FacebookTikTokPinterest and YouTube and @AADskin1 on Instagram.

SOURCE American Academy of Dermatology


These press releases may also interest you

at 03:15
Cresilon Inc. ("Cresilon"), a Brooklyn-based biotechnology company focused on haemostatic medical device technologies, today announced it has entered into a distribution agreement for its revolutionary haemostatic gel, VETIGEL®, to be sold directly...

at 02:30
Ahead of International Tea Day - 21st May 2024  - and with summer inspiring more of us to get off the sofa to be active, a 2024 real-world research study1 reviewed by the tea science experts at the Tea Advisory Panel ? www.teaadvisorypanel.com -...

at 02:30
TreeFrog Therapeutics will participate for the first time at the IAPRD, to present data from their Parkinson's disease cell therapy program, which has demonstrated excellent results with full motor recovery at 16 weeks in preclinical studies.[1]...

at 02:20
Vicore Pharma Holding (STO:VICO)Buloxibutid improved lung function-measured by FVC-by over 200 mL from baseline at 36 weeks of treatment.The therapy was safe and well tolerated with no treatment-related serious adverse events.Biomarker analysis...

at 02:07
GC Biopharma (006280. KS) and Novel Pharma announced that its jointly developed MPS IIIA 'GC1130A' treatment has received FDA IND approval....

at 02:05
PureTech Health plc ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announces the opening of its proposed $100 million tender offer (the "Tender...



News published on and distributed by: